Cardioprotective and metabolic effects of antihypertensive therapy in patients with such comorbidities as arterial hypertension, type 2 diabetes mellitus, and obesity.

Abstract

Today, high rates of growth of such chronic diseases as hypertension, type 2 diabetes mellitus and obesity are noted in the world. The combination of these pathologies increases the risk of developing fatal cardiovascular complications and cardiac mortality tenfold. A reduction in systolic blood pressure of every 10 mmHg, as shown in the UKPDS study (1998), was associated with a 15% reduction in mortality. The most expedient and justified for now is the appointment for complex treatment of patients with comorbid pathology, antihypertensive drugs that inhibit excessive activation of the ranin-angiotensin-aldosterone system (RAAS), in particular, ACE inhibitors and ARB II. This article highlights the main cardioprotective and metabolic properties of these groups of drugs and the specifics of their appointment, taking into account concomitant pathology.